1,667 Shares in Illumina, Inc. (NASDAQ:ILMN) Acquired by 111 Capital

111 Capital purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 1,667 shares of the life sciences company’s stock, valued at approximately $223,000.

Several other institutional investors and hedge funds have also bought and sold shares of ILMN. Golden State Wealth Management LLC bought a new position in Illumina during the 4th quarter worth approximately $32,000. Fourth Dimension Wealth LLC bought a new stake in shares of Illumina in the 4th quarter worth approximately $40,000. Assetmark Inc. grew its position in shares of Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after buying an additional 296 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Illumina in the 4th quarter worth approximately $45,000. Finally, Lee Danner & Bass Inc. bought a new stake in shares of Illumina in the 4th quarter worth approximately $48,000. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ILMN. Guggenheim cut their price objective on Illumina from $122.00 to $114.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. Hsbc Global Res lowered Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. Citigroup cut their price objective on Illumina from $90.00 to $85.00 and set a “neutral” rating on the stock in a research report on Monday, April 7th. TD Cowen lowered Illumina from a “buy” rating to a “hold” rating and cut their price objective for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. Finally, Canaccord Genuity Group cut their price objective on Illumina from $92.00 to $87.00 and set a “hold” rating on the stock in a research report on Monday, May 12th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $128.15.

Insiders Place Their Bets

In other Illumina news, CFO Ankur Dhingra bought 6,100 shares of Illumina stock in a transaction on Monday, May 12th. The stock was acquired at an average price of $81.21 per share, with a total value of $495,381.00. Following the acquisition, the chief financial officer now owns 24,906 shares in the company, valued at approximately $2,022,616.26. This trade represents a 32.44% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 2.60% of the company’s stock.

Illumina Stock Down 3.5%

Shares of NASDAQ:ILMN opened at $81.37 on Friday. The stock has a market capitalization of $12.88 billion, a price-to-earnings ratio of -10.60, a PEG ratio of 1.60 and a beta of 1.35. The stock has a fifty day simple moving average of $77.73 and a two-hundred day simple moving average of $106.64. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.96 by $0.01. The business had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.03 billion. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. The company’s quarterly revenue was down 1.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.98 EPS. On average, research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.